Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

Overview of attention for article published in Biomarker Research, April 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#22 of 372)
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 3 patents

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 56 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

DOSING REGIMENS OF SIRP ALPHA FUSION PROTEINS FOR TREATMENT OF CANCER

Application WO-2023228044-A1

World Intellectual Property Organisation (WIPO)

METHODS FOR MANIPULATING PHAGOCYTOSIS MEDIATED BY CD47

Grant EP-3056515-B1

European Patent Office

METHODS FOR MANIPULATING PHAGOCYTOSIS MEDIATED BY CD47

Grant EP-3056514-B1

European Patent Office

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.